Acute Coronary Syndrome, Acute Myocardial Infarction
Conditions
Keywords
Troponin, acute myocardial injury, acute myocardial infarction, Siemens POC, Siemens POC Atellica® VTLi, Siemens POC HS cTn-I
Brief summary
The Siemens POC High Sensitivity Troponin-I Test System is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I (cTn-I) in fresh human capillary (fingerstick) whole blood, and lithium-heparinized venous whole blood or plasma, to be used by healthcare professionals at the point of care (POC) as well as in the clinical laboratory. The Siemens POC High Sensitivity Troponin-I Test System is to be used as an aid in the diagnosis of myocardial infarction (MI).
Detailed description
Study purpose/objective: * Evaluate the clinical performance of the Siemens POC HS cTn-I test system for the diagnosis and rule out of AMI in patients presenting to the emergency department in whom serial cTnI measurements are obtained on clinical indication. * Correlate the blood and plasma outcomes on the Siemens POC HS cTn-I test system as function of the corresponding hematocrit (Hct) values. Hypothesis: The Siemens POC HS cTn-I Test System will offer an excellent diagnostic performance for acute myocardial injury and acute myocardial infarction, as well as expedite the risk stratification of patients for early discharge from the emergency department.
Interventions
DIAGNOSTIC_TESTCardiac Troponin Testing
Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
Sponsors
Siemens Healthineers
Hennepin Healthcare Research Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Presents to the ED, or ambulatory care center equivalent, with signs or symptoms suspicious of a possible ACS event. 2. Baseline cTn-I measurement and one additional cTn-I measurement at two hours after the first measurement. 3. At least one 12-lead electrocardiogram
Exclusion criteria
1. Less than 21 years old 2. Pregnancy 3. Trauma 4. Declines to participate or has indicated that their blood/ medical information cannot be used for investigational purposes 5. Did not present through the ED 6. Transferred from an outside hospital or clinic.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact on the incidence of myocardial injury and myocardial infarction diagnoses. | Day 1 | Examine the potential impact on the incidence of myocardial injury and myocardial infarction diagnoses using hs-cTnI upon clinical practice implementation with a comparison to the hospital's final ICD-10 code diagnosis of type 1 and type 2 MIs. |
| Examine the incidence of undetectable(<LoD), measurable (LoD - 99th percentile), and increased (>99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System | Day 1 | Examine the incidence of undetectable(\<LoD), measurable (LoD - 99th percentile), and increased (\>99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System in comparison to a high sensitivity cTnI assay (Abbott & Siemens Healthineers) to determine the potential impact on positivity rate, defined by sex-specific 99th percentiles. |
| Examine Concordance | Day 1 | Examine concordance (dis) between hs-cTnI in comparison to a high sensitivity (Abbott & Siemens Healthineers) cTnI assay |
| Examine the diagnostic performance for acute myocardial injury and acute myocardial infarction | Day 1 | Examine the diagnostic performance for a) acute myocardial injury and b) acute myocardial infarction based on various diagnostic strategies using hs-cTnI measurement(s), as follows: 1. Single measurement strategies 1. Limit of detection (LoD) 2. Concentration threshold tailored to meet a clinical need: Derive an optimal rule-out ng/L cutoff for Siemens POC HS cTn-I Test System. 2. Accelerated serial sampling (0/2h protocol) 1. Using the both sex-specific and overall 99th percentiles 2. Delta (absolute concentration serial change value, 0-2h) analysis |
| Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs | Day 1 | Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs, including patients categorized with acute myocardial injury and acute myocardial infarction, including type 1 and 2 myocardial infarction following the 4th Universal Definition of Myocardial Infarction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac mortality | up to 30 days | death due to cardiac reasons |
| Adjudicated index acute myocardial infarction according to 4th UDMI | on admission | acute myocardial infarction, including sub-types following the Fourth Universal Definition of Myocardial Infarction |
| Safety Outcome - MACE | 30 days | Major Adverse Cardiovascular Event - cardiac death, myocardial infarction, revascularization, congestive heart failure |
| All-cause mortality | up to 30 days | any death |
Countries
United States
Outcome results
None listed